Last reviewed · How we verify
Rituximab 375
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.
At a glance
| Generic name | Rituximab 375 |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Drug class | CD20-targeting monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Rituximab targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B cell depletion. This mechanism is effective in B-cell malignancies and autoimmune diseases where B cells play a pathogenic role.
Approved indications
- Non-Hodgkin's lymphoma (B-cell)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Infections
- Cytopenias (anemia, thrombocytopenia, neutropenia)
- Fatigue
- Fever
- Tumor lysis syndrome
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL (PHASE2)
- CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |